TScan Therapeutics, Inc. (TCRX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$0.3400−$0.0090 (−2.58%) on the dayAs of the close; data may be delayed.
TCRX price, last 12 months
Key stats
- Previous close
- $0.3490
- Open
- $0.3454
- Day range
- $0.3300 – $0.3700
- 52-week range
- $0.2902 – $2.57
- Volume
- 377.1K
- Avg volume (20 days)
- 1.4M
- Market cap
- $23.0M
Performance
1W+9.0%
1M−56.3%
3M−64.9%
6M−67.0%
YTD−66.0%
1Y−81.5%
vs S&P 500, 1Y−98.3 pts
Technicals and fundamentals
About TScan Therapeutics, Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $23.0M